CD44 and neoplasm: In contrast to in vitro data, we observed a significant inhibition of tumor growth in vivo in MDA-MB-231 cells (95-98% CD44+/CD24−/low; relatively high level of OCT3/4) in contrast to MCF-7 or T-47D cells (1-10% CD44+/CD24−/low; relatively low level of OCT3/4) upon TRIM28 knockdown (Figure 4 and Supplementary Figure S4).